MedTrace Logo

OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy

NCT02355782 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2015-04-15

No results posted yet for this study

Summary

The purpose of this compassionate use study, for two patients with thrombotic microangiopathy, is to provide expanded access to patients who have participated in the clinical trial OMS721-TMA-001 and in whom improvement in their disease markers was observed while on treatment or to patients who could otherwise benefit from the treatment. This is a treatment protocol; not a research protocol.Therefore, only patients in study OMS721-TMA-001 deemed eligible by the investigator may participate.

Conditions

Interventions

BIOLOGICAL

OMS721

Human IgG4 MASP-2 Monoclonal Antibody

Sponsors & Collaborators

  • Michal Nowicki

    lead OTHER

Principal Investigators

  • Michal Nowicki, MD, PhD · Medical University of Lodz

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02355782 on ClinicalTrials.gov